首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Leukemia & Lymphoma

Leukemia & Lymphoma杂志,由Informa Healthcare出版,于1989年创刊,Monthly,出版语言English,ISSN:1042-8194,E-ISSN:1029-2403。

投稿咨询
Leukemia & Lymphoma
Leukemia & Lymphoma
Leukemia & Lymphoma
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
4区
影响因子
2.1
CiteScore
3.9
期刊收录
SCI、SCIE

Leukemia & Lymphoma(中文译名:《白血病和淋巴瘤》),ISSN:1042-8194,EISSN:1029-2403,是Informa Healthcare出版的国际性学术期刊,创刊于1989年,以Monthly形式稳定发行,2026年总发文量约214篇。该刊采用非OA开放访问,学科归属为医学 - 血液学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.1,2025年期刊CiteScore为3.9,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Leukemia & Lymphoma长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约1.8月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、GERMANY (FED REP GER)、France、England、Australia等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMMAYO CLINIC、CORNELL UNIVERSITY、MEMORIAL SLOAN KETTERING CANCER CENTER、HARVARD UNIVERSITY、ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)、DANA-FARBER CANCER INSTITUTE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
4区 4区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
4区 4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
4区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q3 61 / 103

41.3

学科:ONCOLOGY SCIE Q3 236 / 333

29.3

学科:HEMATOLOGY SCIE Q3 67 / 103

35.44

学科:ONCOLOGY SCIE Q3 249 / 333

25.38

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q3 51 / 99

49

学科:ONCOLOGY SCIE Q3 217 / 328

34

学科:HEMATOLOGY SCIE Q3 66 / 100

34.5

学科:ONCOLOGY SCIE Q3 240 / 328

26.98


中国学者近期发文

1
Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospect

Author:Wu, Jun; Dong, Haibo; Xu, Xuejing; Wang, Mei

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2649879

2
Umbilical cord-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a real-world stud

Author:Niu, Yanyan; Chen, Bin; Zhao, Yaqian; Yu, Xinru; Wang, Tao; Ma, Liangming

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2634172

3
MBP1 inhibits AML proliferation through downregulating noncanonical Wnt/Ca2+ signaling pathwa

Author:Gao, Beibei; Yan, Wenli; Xue, Jingjing; Zhang, Shanshan; Wang, Furong; Kang, Zhijie; Ren, Jinhong; Yan, Jinsong; Wang, Haina

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2661083

4
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphom

Author:Hu, Lina; Lu, Bo; Wei, Xiaolei; Wang, Ying; Xie, Mian; Li, Jun; Feng, Chun; Li, Guoqiang; Qiu, Xiao; Zhang, Jiahe; Guo, Xutao; Zhong, Zhiren; Li, Xiaoqing; Zhang, Qian; Zhou, Jihao

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2654977

5
Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicit

Author:Tian, Ji-xin; Liao, Ying-xi; Wang, Xiao-xu; Wang, Xiao-dan; Li, Shan; Liu, Dong-xue; Sun, Xin-yuan; Zhang, Ping; Miao, Wen-juan

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2634179

6
Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 tria

Author:Wei, Chong; Su, Liping; Liu, Lihong; Zhou, Daobin; Zhang, Wei

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2631800

7
Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysi

Author:Hao, Xiaoyu; Zhang, Jiabin; Liu, Shuozi; Luo, Lan; Li, Chunyuan; Zhang, Weilong; Wang, Jing; Yang, Ping; Jing, Hongmei

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2637864

8
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinio

Author:Kim, Won Seog; Al Mansour, Mubarak; Cheah, Chan; Farias, Joao Samuel De Holanda; Elghandour, Ashraf; Hawkes, Eliza; Huang, Haiwen; Ko, Bor Sheng; De Farias, Danielle Leao Cordeiro; Li, Zhiming; Ong, Shin Yeu; Pavlovsky, Miguel Arturo; Zincer, Fernando Perez; Song, Yuqin

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2640453

9
Reduced-dose anti-thymocyte globulin combined with post-transplant cyclophosphamide versus standard ATG for graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplantation: a focus on chronic GVHD reductio

Author:Guo, Wenyi; Li, Bo; Tang, Li; Peng, Liang; Guo, Shuli

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2645932

10
Coexistence of BCR::ABL1 with IKZF1::ETV6 fusion in an adult patient with acute B-lymphoblastic leukemi

Author:Tan, Kai-Wen; Xu, Yi; Huang, Yuan-Hong; Qiu, Qiao-Cheng; Lyu, Xiao-Yu; Huang, Si-Man; Wang, Zi-Hao; Li, Hui-Ying; Xu, Shun-Zhe; Liu, Fang-Tong; Liu, Shen-Hao; Zhang, Yang; Xue, Sheng-Li; Dai, Hai-Ping

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2621828


在线咨询

Leukemia & Lymphoma

国际简称:LEUKEMIA LYMPHOMA参考译名:白血病和淋巴瘤

年发文量:214 CiteScore:3.9 是否预警:否 Gold OA文章占比:12.17% 研究类文章占比:72.90%

杂志社联系方式:TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON, ENGLAND, OXON, OX14 4RN

Leukemia & Lymphoma